Cetrelimab Biosimilar – Anti-PDCD1, PD1, CD279 mAb – Research Grade

Description of Cetrelimab Biosimilar - Anti-PDCD1, PD1, CD279 mAb - Research Grade

Introduction

Cetrelimab Biosimilar, also known as Anti-PDCD1, PD1, CD279 mAb – Research Grade, is a monoclonal antibody that has been developed as a biosimilar to the therapeutic antibody Cetrelimab. This antibody targets three proteins, PDCD1, PD1, and CD279, which are all involved in regulating the immune response. In this article, we will discuss the structure, activity, and potential applications of Cetrelimab Biosimilar.

Structure of Cetrelimab Biosimilar

Cetrelimab Biosimilar is a monoclonal antibody, meaning it is made up of identical immune cells that have been cloned from a single parent cell. It is a humanized antibody, which means it has been modified to have a structure that is more similar to human antibodies, reducing the risk of adverse reactions. Cetrelimab Biosimilar is a type of immunoglobulin G (IgG) antibody, which is the most abundant type of antibody in the human body. It is made up of two heavy chains and two light chains, and each chain contains a variable region that is specific to its target proteins, PDCD1, PD1, and CD279.

Activity of Cetrelimab Biosimilar

Cetrelimab Biosimilar works by binding to and blocking the activity of PDCD1, PD1, and CD279. These proteins are all involved in regulating the immune response, and by blocking their activity, Cetrelimab Biosimilar can enhance the body’s ability to fight against diseases. PDCD1, also known as programmed cell death protein 1, is a receptor found on the surface of immune cells. When it binds to its ligand, PD-L1, it inhibits the activity of immune cells, leading to a weakened immune response. Similarly, PD1 and CD279 also play a role in regulating the immune response. By blocking these proteins, Cetrelimab Biosimilar can help to restore the immune system’s ability to fight against diseases.

Applications of Cetrelimab Biosimilar

Cetrelimab Biosimilar has potential applications in the treatment of various diseases, particularly those related to the immune system. One of its main uses is in the treatment of cancer. By blocking the activity of PDCD1, PD1, and CD279, Cetrelimab Biosimilar can enhance the immune response against cancer cells, making it a promising therapeutic option for various types of cancer. It is currently being studied in clinical trials for the treatment of melanoma, non-small cell lung cancer, and other solid tumors.

In addition to cancer, Cetrelimab Biosimilar may also have potential applications in the treatment of autoimmune diseases. These diseases occur when the immune system mistakenly attacks healthy cells and tissues in the body. By blocking the activity of PDCD1, PD1, and CD279, Cetrelimab Biosimilar can help to regulate the immune response and reduce the symptoms of autoimmune diseases such as rheumatoid arthritis and multiple sclerosis.

Conclusion

In summary, Cetrelimab Biosimilar is a monoclonal antibody that targets PDCD1, PD1, and CD279, three proteins involved in regulating the immune response. Its structure and activity make it a promising therapeutic option for various diseases, particularly cancer and autoimmune diseases. Further research and clinical trials are needed to fully understand the potential of Cetrelimab Biosimilar in treating these conditions.

Cetrelimab Biosimilar - Anti-PDCD1, PD1, CD279 mAb binds to CD279 Recombinant Protein in indirect ELISA Assay

Immobilized CD279 Recombinant Protein (cat. No.PX-P4117) at 0.5µg/mL (100µL/well) can bind to Cetrelimab Biosimilar - Anti-PDCD1, PD1, CD279 mAb (cat. No.PX-TA1513) in indirect ELISA with Goat Anti-Human IgG secondary antibody coupled with HRP measured by OD450